ACE Inhibitors Market Size and Demand Forecast 2026–2030

Uncover key drivers, emerging technologies, and competitive movements shaping the ace inhibitors market from 2026–2035 with trusted insights from The Business Research Company

Starting from its 2026 valuation, what market size is the ACE Inhibitors Market expected to reach by 2030?

The ace inhibitors market size has demonstrated strong growth over recent years. It is anticipated to expand from $7.41 billion in 2025 to $7.84 billion in 2026, at a compound annual growth rate (CAGR) of 5.8%. This historical expansion can be linked to factors such as the increasing prevalence of hypertension, growing awareness concerning cardiovascular diseases, the introduction of first-generation ace inhibitors, an expanding geriatric population, and advancements in drug formulation.

The ace inhibitors market size is expected to experience significant growth in the coming years. It is projected to expand to $10.11 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.5%. The projected expansion can be attributed to the rising demand for personalized medicine, the integration of digital health solutions, the widening of emerging markets, the development of new ace inhibitor combinations, and an increase in home healthcare services. Major developments anticipated in the forecast period include personalized hypertension management, the use of telemedicine and remote patient monitoring, the evolution of combination therapies, an increase in generic ace inhibitors, and the expansion of home healthcare solutions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What Drivers Are Driving Adoption Within The ACE Inhibitors Market?

The ACE inhibitors market is anticipated to expand due to a projected increase in the occurrence of cardiac disorders. Cardiac disorders are medical conditions that affect the heart or blood vessels, covering a broad spectrum including coronary artery disease, heart failure, and arrhythmias. ACE inhibitors are crucial for managing these conditions as they inhibit the angiotensin-converting enzyme, thereby decreasing vasoconstriction, sodium retention, and aldosterone secretion, which in turn improves cardiac function. As an illustration, the American Heart Association, a US-based non-profit organization, stated in January 2024 that the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Thus, the escalating incidence of cardiac disorders is fueling the growth of the ACE inhibitors market.

How Is The ACE Inhibitors Market Organized Into Various Segments?

The ace inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril, Fosinopril Sodium, Fosinopril Calcium

How Are New Market Trends Shaping The Landscape Of The ACE Inhibitors Market?

Companies prominently featured in the ACE inhibitor market are increasingly dedicated to introducing generic drugs to secure a competitive advantage. A generic drug is a pharmaceutical product that shares the same active ingredients, dosage, safety profile, strength, administration route, and efficacy as its brand-name counterpart, yet is typically available at a lower cost once the original patent expires. For example, in August 2023, Pharmascience Inc., a Canada-based pharmaceutical company, launched pms-PERINDOPRIL-INDAPAMIDE, a generic medication developed for the initial management of mild to moderate essential hypertension (high blood pressure) in adults. This combination therapy features two active components: perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor that contributes to relaxing blood vessels, and indapamide, a chlorosulphamoyl diuretic that aids in the elimination of excess fluid and sodium from the body. These ingredients collectively work in unison to effectively reduce blood pressure in a wide array of patients. pms-PERINDOPRIL-INDAPAMIDE is provided in various strengths, including 2 mg, 4 mg, and 8 mg of perindopril erbumine, paired respectively with 0.625 mg, 1.25 mg, and 2.5 mg of indapamide.

Who Are The Core Companies Influencing Trends In The ACE Inhibitors Market?

Major companies operating in the ace inhibitors market are Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Regions Are Projected To Dominate The ACE Inhibitors Market In The Coming Years?

North America was the largest region in the ACE inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized ACE Inhibitors Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

Browse Through More Reports Similar to the Global ACE Inhibitors Market 2026, By The Business Research Company

Ace Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795